Inhibitory oligonucleotide having the general formula: (I) are disclosed which can be used in pharmaceutical compositions, whereby in formula (I) C is cytidine or a derivative thereof, whereby the cytidine derivative is selected from the group consisting of 5-methylcytidine, a cytidine-like nucleotide having a chemical modification involving the cytosine base, cytidine nucleoside sugar, or both the cytosine base and the cytidine nucleoside sugar, 2'-0-methylcytidine, 5-bromocytidine, 5-hydroxycytidine, ribocytidine and cytosine-P-D-arabinofuranoside, G is guanosine or a derivative thereof, whereby the guanosine derivative is selected from the group consisting of 7-deazaguanosine, a guanosine-like nucleotide having a chemical modification involving the guanine base, the guanosine nucleoside sugar or both the guanine base and the guanosine nucleoside sugar, X1 and X3 is any nucleotide sequence with 0 to 12 bases and each nucleotide is independent of any other, X2 is any nucleotide sequence having 0 to 3 nucleotides, N2 and N3 are each independently any nucleotide, N4 and N7 is a pyrimidine or a modified pyrimidine, N5 is a purin or a modified purin, N6 is a modified pyrimidine, A or a modified purin, wherein at least two of the nucleotides N4, N5, N6 or N7 are modified purins or modified pyrimidines.L'invention porte sur un oligonucléotide inhibiteur répondant à la formule générale : (I), qui peuvent être utilisés dans des compositions pharmaceutiques. Dans la formule (I), C représente la cytidine ou un dérivé de celle-ci, le dérivé de cytidine étant choisi dans le groupe constitué par la 5-méthylcytidine, un nucléotide analogue à la cytidine ayant une modification chimique impliquant la base cytosine, le sucre du nucléoside cytidine ou à la fois la base cytosine et le sucre du nucléoside cytidine, la 2'-o-méthylcytidine, la 5-bromocytidine, la 5-hydroxycytidine, la ribocytidine et le cytosine-P-D-arabinofuranoside ； G représente la guanosine ou un dérivé de celle-ci,
